About

Make an informed decision with an evidence-based assessment

Our approach

Drugs, devices, procedures and health systems technologies are within our assessment portfolio. Our clients comprise decision-makers in government, health services, drug plan management, and industry worldwide. Within 24 hours of submitting a request, we will contact you to discuss your information needs and timelines. We offer a variety of products and services tailored to meet your needs:

Health Technology Assessments
Systematic and Rapid Reviews
Meta-Analyses
Surveys
Customized Reports & Research Services (à la carte)

Our Consultants

Lynda McGahan Evidence-based Healthcare Consultant
With over 19 years of expertise in quantitative and qualitative research methods, Lynda has conducted numerous technology assessments, systematic reviews, meta-analyses, rapid reviews and surveys in a variety of clinical areas. Having served as a Research Officer with the Canadian Agency for Drugs and Technologies in Health, Lynda worked extensively with Canadian decision makers. With an MSc in Pharmacology, she continues to develop her expertise in network meta-analysis and pharmacoeconomics. Lynda is a member of the Society for Medical Decision Making, Health Technology Assessment International, and the Society for Neuroscience. She is a peer reviewer for the National Health Services, United Kingdom, and a Cochrane reviewer.

Professional Development

Survival Analysis (General) & Survival Analysis of Population-Based Data Cancer Sets, Canadian Society for Epidemiology and Biostatistics (CSEB), Ottawa 2014
An Introduction to Network Meta-Analysis, Ottawa 2012
Canadian Cochrane Centre Review Manager Training, Ottawa 2011
Health Technology Assessment: From Theory to Evidence to Policy, Ottawa 2011

more....

Research Publications

McGahan, L. Pembrolizumab (Keytruda®) as first-line therapy for PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No. 91. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2019.
McGahan, L. Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). Horizon Scanning in Oncology No. 89. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; July 2019.
McGahan, L. Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triplenegative breast cancer (aTNBC). Horizon Scanning in Oncology No. 87. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; March 2019.
McGahan, L. Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenstrom’s macroglobulinemia. Horizon Scanning in Oncology No. 85. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2018.
McGahan, L. Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 83. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2018.
McGahan, L. Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 80 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2018.
McGahan, L. Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). Horizon Scanning in Oncology No 78 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; February 2018.
McGahan, L. Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small cell lung cancer after prior chemoradiotherapy. Horizon Scanning in Oncology No 76 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2017.
McGahan, L. Olaparib (Lynparza®️) in patients with BRCA-mutated metastatic breast cancer. Horizon Scanning in Oncology No 71 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2017.
McGahan, L. Ceritinib (Zykadia™) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. Horizon Scanning in Oncology No 69 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2017.
McGahan, L. Atezolizumab (Tecentriq®️) in previously treated non-small cell lung cancer (NSCLC). Horizon Scanning in Oncology No 68 ISSN-online 2076-5940. Vienna: Ludwig Boltzman Institute for Health Technology Assessment; April 2017.
McGahan, L. Palbociclib (Ibrance™) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. Horizon Scanning in Oncology No 64 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; January 2017.
McGahan, L. Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. Horizon Scanning in Oncology No 61 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2016.
Lambert, R, Vreugdenburg, TD, Marlow, N, Scott, NA, McGahan, L, Tivey, D. Practical applications of rapid review methods in the development of Australian health policy. Australian Health Review; accepted for publication 5 June 2016, published online 29 July 2016.
Best practices for increasing attendance at outpatient addictions clinics. Rapid Review August 2015. Canadian Centre for Substance Abuse, freely accessible with login through the Treatment Space at http://www.eenetconnect.ca/g/treatment
McGahan, L, Scott, A. Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines. Rapid Review March 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
McGahan, L, Scott, A. Tonsillectomy, adenoidectomy and adenotonsillectomy for obstructive sleep apnoea: review of clinical evidence and guidelines. Rapid Review February 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
Lopez-Olivo, MA, Amezaga Urruela, M, McGahan, L, Pollono, E.N., Suarez-Almazor, M.E. Rituxumab for rheumatoid arthritis (Review). Cochrane Database of Systematic Reviews 2015, Issue 1. Art.No.: CD007356. DOI: 10.1002/14651858.CD007356.pub2.
McGahan, L, Scott, A. Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines. Rapid Review August 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
McGahan, L, Scott, A. Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines.Rapid Review December 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.

more....

L. McGahan Consulting / Ottawa, ON, Canada / T: 613 867 5497 / E: [email protected]